Skip to content
Companies

Mercury Bio

Intracellular drug delivery across the blood-brain barrier

Raised to date

$1.6M

of $1.6M offered across 2 Form D filings

Investors
1
Last filed
Nov 12, 2026

About

Mercury Bio is a Santa Fe biotechnology company developing intracellular immunotherapeutics, starting with Parkinson's and Alzheimer's disease. Its MB-TIP platform uses engineered exosome-based yEV nanobodies to carry proteins, nanobodies, RNA and small molecules across the blood-brain barrier and into the cytoplasm of neurons. The company is preclinical and says it is advancing lead candidates toward FDA IND filings.

Its patented yEV delivery system is reported to cross the blood-brain barrier and avoid endosomal entrapment, so large-molecule drugs can reach the inside of neurons.

Funding

$1.6M round, first sold Oct 2026$1.6M soldOct 2026
Now
  • EquityFiled Nov 12, 2026Form D
    $1.6M/ $1.6M
  • Option to acquireFiled Nov 12, 2026Form D
    $13K/ $13K

Product

MB-TIP (Targeting Intracellular Pathologies)

Intracellular drug delivery platform

A platform built on engineered yEV exosome-based nanobodies and AI-informed ligand design that delivers engineered immunotherapeutics into cells.

  • YEV engineered nanobody delivery across the blood-brain barrier
  • Cytoplasmic delivery without endosomal degradation
  • AI-informed ligand design

Built for

Patients with neurodegenerative diseases such as Parkinson's and Alzheimer's, and biopharma partners

People on file